Abstract

AIDS: NeXstar Pharmaceuticals has begun marketing DaunoXome (daunorubicin citrate liposome injection), which maximizes the selectivity of daunorubicin for solid tumors. Phase III trials showed the drug to have efficacy comparable to a three-drug regimen of adriamycin, bleomycin, and vincristine (ABV). There was no evidence of cardiotoxicity except at levels greater than six times higher than would normally be tolerated by the patient.